fda warning compounding semaglutide october 2025 Troubling Findings in Study of GLP-1 Compounders Semaglutide Patient Safety Updates |

People Taking Orforglipron Saw Substantial Reductions in Weight and A1C Levels In a 40-week placebo-controlled trial, people with type 2 diabetes taking the highest dose of orforglipron lost 16 pounds on average, or about 7.9 percent of their body weight, and were still losing weight when the study ended

The cost advantage over brand medications is substantial

This surpasses the results typically achieved through diet and exercise alone, making these injectables an excellent choice for those looking to see real change

However, if you have commercial insurance, you may qualify for the Zepbound savings offer , which brings the cost of a one-month prescription of Zepbound another injectable GLP-1 medication down to $25 (with insurance coverage) or $650 (without insurance coverage) and may be a cheaper option if youre looking for a medication to help with weight loss (and not type 2 diabetes)

N Engl J Med, 2023